

**THE UNIVERSITY OF BRITISH COLUMBIA**  
**Curriculum Vitae for Faculty Members**

Date: January 2015

Initials: MJH

1. **SURNAME:** HARRISON **FIRST NAME:** MARK  
**MIDDLE NAME(S):** J

2. **DEPARTMENT/SCHOOL:**

3. **FACULTY:** Pharmaceutical Sciences

4. **PRESENT RANK:** Assistant Professor **SINCE:** August 2014

5. **POST-SECONDARY EDUCATION**

University or Institution	Degree	Subject Area	Dates
University of Manchester	PhD	Epidemiology	September 2004 – May 2008
University of Edinburgh	MSc	Epidemiology	September 2001 – August 2002
University of Bradford	BSC(Hons) 1 <sup>st</sup> class	Business and Management Sciences	September 1996 – May 2000

**Special Professional Qualifications**

6. **EMPLOYMENT RECORD**

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
University of Manchester	Senior Research Fellow	August 2013 – August 2014
University of Manchester	Research Fellow	July 2010 – August 2013
University of Manchester	Research Associate	February 2009 – July 2010
University of Manchester	Research Assistant	August 2002 – February 2009

(b) *At UBC*

Rank or Title	Dates
Assistant Professor, Faculty of Pharmaceutical Sciences	August 2014 -
Scientist, Centre for Health Evaluation and Outcomes Sciences (CHEOS), Providence Health Care Research Institute	August 2014 -

(c) *Date of granting of tenure at U.B.C.:*

7. **LEAVES OF ABSENCE**

University, Company or Organization at which Leave was taken	Type of Leave	Dates

8. **TEACHING**(a) *Areas of special interest and accomplishments*(b) *Courses Taught at UBC*

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2014W	PHAR 506	3		3			
2014W	PHAR 456	3		3			

(c) *Graduate Students Supervised*

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Lynn Rostron, University of Manchester	Master's Equivalent	2010/9	2011/9	Supervisor
Anna Wilding, University of Manchester	Master's Equivalent	2010/9	2011/9	Supervisor
Katherine Gaudreau, London School of Hygiene & Tropical Medicine	Master's Thesis	2009/9	2010/9	Supervisor
Alexander Turner, University of Manchester	Doctorate	2013/9		Co-supervisor
Sean Gavan, University of Manchester	Doctorate	2013/9		Co-supervisor

Rachel Meacock, University of Manchester	Doctorate	2012/9		Co-supervisor
Eleanor Heather, University of Sheffield	Master's Thesis	2011/9	2013/9	Co-supervisor

(d) *Continuing Education Activities*

2009-2014 MSc Epidemiology, London School of Hygiene & Tropical Medicine.  
Moderation of online learning environments, supervision of dissertation modules, marking of exam papers.

(e) *Visiting Lecturer (indicate university/organization and dates)*

August 2014 (to date) - Honorary Senior Research Fellow in Health Economics, Manchester Centre for Health Economics, University of Manchester UK

(f) *Other*

Workshops

- Vienna Healthcare Lectures, Gesundheitsförderung und Prävention, Vienna, Austria (2012).  
Two 90 minute lectures during a 3-day course for health policy makers in Austria, delivered by speakers from a range of European health care systems. Lectures with worked examples, followed by group discussions, both covering policy initiatives in the English National Health Service: (1) the NHS Patient Reported Outcome Measure Project, and (2) the role of the National Institute for Health and Care Excellence (NICE).
- National Institute for Health Research North West Research for Patient Benefit Workshops, Greater Manchester, UK (since 2010).  
A series of workshops aimed at clinical researchers applying for open competition, peer reviewed funding streams. Presentations cover the funding application process, the role of the Research Design Service in supporting researchers applying for funding, and a health economics presentation showcasing the areas of expertise of the Centre for Health Economics.

## 9. **SCHOLARLY AND PROFESSIONAL ACTIVITIES**

(a) *Areas of special interest and accomplishments*

### **Key Theory / Methodology**

Health economics

#### *Economic evaluation*

Methods to value the benefits and harms, and the non-health benefits of health interventions. These methods have included the application and evaluation of generic preference-based measures for use in quality-adjusted life year (QALY) based economics evaluations. The use of choice based methods for eliciting preferences for different aspects of health care interventions such as risk:benefit trade-offs and preferences for the process of health care delivery. Extensions of these methods to allow preferences to be expressed in units amenable for use in QALY based cost-effectiveness analyses.

Evaluation of the cost-effectiveness of health interventions. Methodological expertise in this area includes trial-based analyses (using incremental cost-effectiveness ratios, cost-effectiveness acceptability curves, and the net-benefit framework) and decision-analytical modelling techniques (including Markov models and discrete-event simulation) used to simulate the expected value of interventions over extended time horizons, populations, and multiple comparators.

### *Policy research*

Econometric based methods for policy evaluation, with methodological expertise in this area centred on regression based methods for the analysis of administrative data. Random effects and fixed effects regression models for panel data and differences-in-differences and interrupted time series models for the evaluation of specific policy changes.

### *Epidemiology*

Registry-based studies of the safety of pharmaceutical interventions. Methodological expertise in this area includes analysis of case-control studies using incidence rate-ratios to estimate the relative risk of adverse outcomes in those treated compared with untreated patients and survival analysis to account for time to event data.

Validation of outcome measures for health-related quality of life and preference-based measures using tests of construct, criterion and discriminant validity.

The maintenance and analysis of workforce registers for planning provision of services with a focus on inequalities in provision. Methodological expertise in this area includes benchmarking of observed and expected levels of provision, use of standardised testing rates to identify under/over provision of service, and capture-recapture methods to account for variable ascertainment of prevalence of health needs.

Analysis of secondary data using a range of regression based methods to address issues beyond the primary aim of specific randomised-controlled trials and prospective studies.

### **Research Interests**

My research program centres on the use of decision analysis to promote the delivery of sustainable patient-centred health care. My research focusses on studies aimed at improving at providing patients with the right type of care at the right point in the treatment pathway, and care that is delivered consistently with their preferences.

#### *Optimizing the provision of current treatment*

Current practice is the benchmark against which new, typically costly, treatments are evaluated. To ensure only the most cost-effective new treatments are adopted, it is important to understand how to use current treatment options to their full potential. Promoting the routine use of generic patient reported outcome measures and the collection of primary data to allow the quantification of health impacts and enable comparison of these impacts across a range of disease and treatment settings.

#### *Treating patients earlier in the pathway and in the community setting*

The role of providers of care at the first point of contact, such as family doctors and pharmacists, and the potential they have to prevent disease and to improve the health of the populations they serve. These roles have the potential to contain costs to the health care system, particularly those arising from chronic disease. My interest has been in the role of primary care providers in prevention of resource use in more specialised hospital settings resulting from acute disease related events. To date this has focussed on the role of screening for diseases in targeted populations and incentivization of primary care for people with ambulatory care sensitive conditions. Use of regression-based methods to analyse data from large routinely collected datasets to answer questions about the effectiveness of treatments in preventing

consequences that are damaging to a patient's health and costly to a health service payer. Assessment of the potential impact of screening programmes using decision-analytical models such as Markov models and discrete-event simulation.

### *Patient preferences*

Patient-centred care, particularly that decisions and recommendations have to be made that are aligned with the preferences and values of the patient. Using choice based methods to understand the treatment-related decisions that patients make, how they trade-off risks and benefits of treatments, and how they trade-off the process of healthcare delivery with these health risks and benefits. Methodological interests in this area include improvement of health risk information to patients.

### *Stratified medicine*

Stratified medicine brings my interests together into a single theme of research. Work has included projects scoping the potential for stratified medicines in chronic rheumatologic conditions, initially rheumatoid arthritis and systemic lupus erythematosus (SLE). This includes methods for evaluating the cost-effectiveness of a stratified medicine approach, the impact on the treatment pathway, and barriers to the success of this approach arising from patient and physician preference for treatments.

Disciplines Trained In: Epidemiology and biostatistics, Economics, Business Administration, Management

(b) *Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))*

<b>Granting Agency</b>	<b>Subject</b>	<b>COMP</b>	<b>\$ Per Year</b>	<b>Year</b>	<b>Principal Investigator</b>	<b>Co-Investigator(s)</b>
Michael Smith Foundation for Health Research	Analysis of Accelerated Integrated Primary and Community Care (aIPCC) Data	C	\$100,00 total	2014 – 2015	Dr. K. McGrail	Dr. M. Law Dr. M. McGregor Dr. S. Berg Dr. C. Mitton Dr. S. Wong Dr. S. Bryan Dr. M. Harrison
National Institute for Health Research (NIHR) (UK)	Cost effectiveness analysis of pharmacological interventions in paediatric rheumatology	C	93,000 Pound sterling total	2013 – 2015		Dr. M. Harrison
Central Manchester Foundation Healthcare Trust	Haemophilia health economics: Immune Tolerance Study	NC	28,942 Pound sterling total	2012 – 2014	Dr. M. Harrison	
National Institute for Health Research (NIHR) (UK)	Developing, testing and implementing the NSPCR Patient Safety Toolkit in general practices in England	C	599,740 Pound sterling total	2012 – 2015		Dr. M. Harrison

National Institute for Health Research (NIHR) (UK)	Evaluating the efficacy of the Promoting Alternative Thinking Strategies (PATHS) curriculum in promoting social and emotional wellbeing among children in primary school: a cluster randomized controlled trial	C	1,250,858 Pound sterling total	2012 – 2017		Dr. M. Harrison
National Institute for Health Research (NIHR) (UK)	A pilot randomized controlled trial comparing patient-reported and clinical outcomes in edentulous patients with standard implant-retained overdentures and mini-implant-retained overdentures in heavily resorbed mandibular ridges	C	240,714 Pound sterling total	2013 – 2015		Dr. M. Harrison
National Institute for Health Research (NIHR) (UK)	Culturally-adapted family intervention (CaFI) for African Caribbeans with schizophrenia and their families: A feasibility study of implementation and acceptability	C	353,173 Pound sterling total	2014 – 2017		Dr. M. Harrison
National Institute for Health Research (NIHR) (UK) Methods Fellowships	Cost of illness of open surgical wounds and cost-effectiveness of negative pressure wound therapy for the treatment of severe pressure ulcers	C	93,000 Pound sterling total	2014 – 2016		Dr. M. Harrison
National Institute for Health Research (NIHR) (UK)	Stroke reduction via improved opportunistic screening for atrial fibrillation. An evaluation of the clinical and economic benefits of the RapidRhythm device within primary care	C	873,704 Pound sterling total	2014 – 2016		Dr. M. Harrison
Medical Research Council (UK)	Attribution of patient reported outcomes to the effects of care providers	C	422,094 Pound sterling total	2010 - 2014		Dr. M. Harrison
Manchester Academic Health Sciences Centre	The health economic impact of implementing flexiscope screening of the large bowel across Manchester	C	21,866 Pound sterling total	2010 – 2013		Dr. M. Harrison

- (c) *Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)

- (d) *Invited Presentations*

- Invited to present at C2E2 Rounds. Centre for Clinical Epidemiology and Evaluation (C2E2) Rounds, Vancouver Coastal Health Research Institute, Vancouver, BC, June 22, 2015.
- Sustainable Healthcare – Looking for the Answers Within the System. Rx&D Innovation and Healthcare Sustainability Policy Forum, Vancouver, BC, January 26, 2015.
- Initiative for Sustainable Healthcare. Launch. UBC Faculty of Pharmaceutical Sciences, Vancouver, BC, January 21, 2015.
- Primary care pay-for-performance in England. Were emergency admissions for ambulatory care sensitive conditions reduced? UBC School of Population and Public Health, Vancouver, BC, October 9, 2014.
- Sustainability in health care: Looking for answers within. Work in Progress Seminar Series, St. Paul's Hospital, Vancouver, BC, September 10, 2014.
- Does waiting time influence the effectiveness of surgery? Lessons from the NHS PROMS Project in the UK. Centre for Clinical Epidemiology and Evaluation Rounds, Vancouver General Hospital, Vancouver, BC, June 2013.
- Towards a reference approach to derive QALYs for economic evaluations in rheumatology. OMERACT (Outcome Measures in Rheumatology) Group, University of Toronto, Canada, May 2008.

- (e) *Other Presentations*

- (f) *Other*

- (g) *Conference Participation (Organizer, Keynote Speaker, etc.)*

- 2012 Co-applicant for an organised session accepted for the International Health Economics Association (iHEA) conference, Sydney July 2013: "Breaking the Addiction to Adoption in Health Economics: Perspectives from Australia, Scotland, Canada and England"  
With: Professor Stirling Bryan, University of British Columbia.
- 2009-2010 Lead organisational role for the OMERACT Quality-Adjusted Life Years (QALY) Special Interest Group session which was upgraded to an OMERACT Patient Perspective Virtual Campus at the OMERACT 10 International Conference in Kota Kinabalu, Malaysia 2010.

Discussant at national and international conferences:

- 2012 Health Economists' Study Group. Aix-en-Provence, France.  
2012 Nordic Health Economists' Study Group. Kuopio, Finland.

## 10. **SERVICE TO THE UNIVERSITY**

(a) *Areas of special interest and accomplishments*

(b) *Memberships on committees, including offices held and dates*

(c) *Other service, including dates*

- External Examiner, Zafar Zafari, PhD Candidate, Comprehensive Examination, Faculty of Experimental Medicine, UBC, September 30, 2014.

## 11. **SERVICE TO THE COMMUNITY**

(a) *Memberships on scholarly societies, including offices held and dates*

- 2014-present Society for Medical Decision Making (SMDM)
- 2014-present Canadian Rheumatology Association
- 2010-present International Health Economics Association (iHEA)
- 2008- present UK Health Economists' Study Group (HESG)
- 2008-2011 Outcome Measures in Rheumatology (OMERACT)

(b) *Memberships on other societies, including offices held and dates*

2009-2011 Invited Fellow for the Quality-Adjusted Life Years (QALY) Special Interest Group, Outcome Measures in Rheumatology (OMERACT) arising from the OMERACT 9 Conference.

2008 OMERACT (Outcome Measures in Rheumatology) – 'Towards a reference approach to derive QALYs for economic evaluations in rheumatology':, University of Toronto, Canada.

(c) *Memberships on scholarly committees, including offices held and dates*

(d) *Memberships on other committees, including offices held and dates*

(e) *Editorships (list journal and dates)*

- Associate Editor, BMC Health Services Research, 2011-present
- Section Editor (Health Economics and Quality of Life), Current Rheumatology Reports, 2015
- Section Editor (Health Economics and Quality of Life), Current Rheumatology Reports, 2014

(f) *Reviewer (journal, agency, etc. including dates)*

- Reviewer for 16 journals:



Health Economics, Paediatrics, Value in Health, Pharmacoeconomics, Social Science & Medicine, Quality of Life Research, Implementation Science, Patient Education and Counseling, Arthritis Care & Research, Annals of the Rheumatic Diseases, Rheumatology, Archives of Diseases in Childhood, Clinical and Experimental Rheumatology, The Journal of Rheumatology, Current Medical Research & Opinion, Current Rheumatology Reports  
 Reviewer for NIHR Programme Grants for Applied Research, 2010-2014.

(g) *External examiner (indicate universities and dates)*

(h) *Consultant (indicate organization and dates)*

- Frontline Advisor and Health Economics Advisor, Consultation Service, The NIHR Research Design Service North, 2010/1 – 2012/12
- Consultancy, Consultation Service, Greater Manchester and Chestire Stroke Network, 2011/1 – 2011/12

(i) *Other service to the community*

## 12. **AWARDS AND DISTINCTIONS**

(a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

(b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

2009	European League Against Rheumatology Travel Bursary (€600 + Registration Costs)
2008	Postgraduate student of the year, University of Manchester
2008	Awarded position as OMERACT Fellow for the OMERACT QALY Group
2002	Medical Research Council, Masters Advanced Course Studentship

(c) *Awards for Service (indicate name of award, awarding organizations, date)*

(d) *Other Awards*

## 13. **OTHER RELEVANT INFORMATION (Maximum One Page)**

**THE UNIVERSITY OF BRITISH COLUMBIA**  
***Publications Record***

SURNAME: HARRISON

FIRST NAME: Mark  
MIDDLE NAME(S):Initials: MJH  
Date: January 2015**1. REFEREED PUBLICATIONS***(a) Journals*

1. **Harrison M**, Marra C, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a discrete choice experiment. *Rheumatology*. January 2015. Accepted.
2. **Harrison M**, Birch S, Eden M, Ramsden S, Farragher T, Payne K, Hall G, Black GC. Variation in healthcare services for specialist genetic testing and implications for planning genetic services: the example of inherited retinal dystrophy in the English NHS. *J Community Genet*. 2015 Jan 9. [Epub ahead of print]. PMID: 25567483
3. Meacock R, **Harrison M**, McElhone K, Abbott J, Haque S, Bruce I, Teh LS. Mapping the disease-specific LupusQoL to the SF-6D. *Qual Life Res*. 2014 Dec 16. [Epub ahead of print]. PMID: 25510215
4. **Harrison MJ**, Dusheiko M, Sutton M, Gravelle H, Doran T, Roland M. Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal study. *British Medical Journal*. 2014 Nov 11;349:g6423. doi: 10.1136/bmj.g6423. PMID: 25389120
5. Gavan S, **Harrison M**, Iglesias C, Barton A, Manca A, Payne K. Economics of stratified medicine in rheumatoid arthritis. *Current Rheumatology Reports*. 2014 Dec;16(12):468. doi: 10.1007/s11926-014-0468-x. PMID: 25366935
6. Heather E, Payne K, **Harrison M**, Symmons D. Including adverse drug events in economic evaluations of anti-tumour necrosis factor- $\alpha$  drugs for adult rheumatoid arthritis: A systematic review of economic decision analytic models. *Pharmacoeconomics*. 2014; 32(2):109-34. PMID: 24338344
7. **Harrison MJ**, Rigby D, Vass C, Flynn T, Louviere J, Payne K. Risk as an attribute in discrete choice experiments: A systematic review of the literature. *Patient*. 2014; 7(2):151-70.
8. Bujkiewicz S, Thompson JR, Sutton AJ, Cooper NJ, **Harrison MJ**, Symmons DPM, Abrams KR. Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis. *Value Health*. 2014; 17(1):109-15. PMID: 24438724
9. Bujkiewicz S, Thompson J, Sutton A, Cooper N, **Harrison MJ**, Symmons D, Abrams KR. Multivariate meta-analysis of mixed outcomes: A Bayesian approach. *Stat Med*. 2013; 32(22):3926-43.
10. Meacock R, Dale N, **Harrison MJ**. The humanistic and economic burden of systemic lupus erythematosus (SLE): A systematic review. *Pharmacoeconomics*. 2013; 31(1):49-61. PMID: 23329592
11. **Harrison M**, Ahmad Y, Haque S, Dale N, Teh L, Snowden N, Ho P, Gorodkin R, Bruce I. Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus. *Journal of Rheumatology*. 2012; 39(4):735-42.
12. **Harrison M**, Reeves D, Harkness E, Valderas J, Kennedy A, Rogers A, Hann M, Bower P. A secondary analysis of the moderating effects of depression and multimorbidity on the effectiveness of a chronic disease self-management programme. *Patient Education and Counseling*. 2012; 87(1):67-83. PMID: 21767927
13. **Harrison M**, Fullwood C, Bower P, Kennedy A, Rogers A, Reeves D. Exploring the mechanisms of change in the chronic disease self-management programme: Secondary analysis of data from a randomized controlled trial. *Patient Education and Counseling*. 2011; 85(2):e39-e47.
14. Kirwan J, Boonen A, **Harrison M**, Hewlett S, Wells G, Singh J, Furst D, Dworkin R. OMERACT 10 Patient Perspective Virtual Campus: Valuing Health; Measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. *Journal of Rheumatology*. 2011; 38(8):1728-34. PMID: 21807793
15. **Harrison M**, Bansback N, Marra C, Drummond M, Tugwell P, Boonen A. Valuing health for clinical and economic decisions: Directions relevant for rheumatologists. *Journal of Rheumatology*. 2011; 38(8):1770-5. PMID: 21807800

16. Foster H, **Harrison M**, Pain C, Symmons D, Baidam E. Delivery of paediatric rheumatology care in the UK – The projected shortfall. *Clinical Rheumatology*. 2011; 30(5):679-83.
17. Camacho E, **Harrison M**, Farragher T, Lunt M, Bunn D, Verstappen S, Symmons D. Parity, time since last live birth and long-term functional outcomes: A study of women participating in the Norfolk Arthritis Register. *Annals of the Rheumatic Diseases*. 2011; 70(4):642-5.
18. **Harrison MJ**, Lee S, Deighton C, Symmons DPM. UK Rheumatology Consultant Workforce Provision 2007-9: Results from the BSR/Arthritis Research UK Consultant Workforce Register. *Clinical Medicine*. 2011; 11(2):119-24.
19. Barta Z, **Harrison M**, Wangrangsimakul T, Shelmerdine J, The L, Patrick M, Edlin H, Dale N, Ahmad Y, Bruce I. Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. *Lupus*. 2010; 19(3):231-8.
20. **Harrison M**, Lunt M, Verstappen S, Watson K, Bansback N, Symmons D. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. *Health and Quality of Life Outcomes*. 2010; 11(8):21.
21. **Harrison M**, Boonen A, Tugwell P, Symmons D. Same question, different answers: A comparison of global health assessments using visual analogue scales. *Quality of Life Research*. 2009 Dec; 18(10):1285-92.
22. **Harrison M**, Davies L, Bansback N, McCoy M, Verstappen S, Watson K, Symmons D. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. *Quality of Life Research*. 2009; 18(9):1195-205.
23. **Harrison M**, Farragher T, Clarke A, Manning S, Bunn D, Symmons D. Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritis. *Arthritis and Rheumatology*. 2009; 61(10):1297-304.
24. **Harrison MJ**, Davies LM, Bansback NJ, McCoy MJ, Farragher TM, Verstappen SS, Hassell A, Symmons D. Why do patients with inflammatory arthritis often score states “worse than death” on the EQ-5D? An investigation of the EQ-5D classification system. *Value in Health*. 2009; 12(6):1026-34.
25. Boonen A, Maetzel A, Drumond M, Suarez-Almazor M, **Harrison M**, Welch V, Tugwell P. The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. *Journal of Rheumatology*. 2009; 36(9):2045-9.
26. **Harrison MJ**, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DPM. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor  $\alpha$  therapy: Results from the British Society for Rheumatology Biologics Register. *Annals of the Rheumatic Diseases*. 2009; 68(2):209-215.
27. **Harrison MJ**, Deighton C, Symmons D. An update on the UK Rheumatology Consultant Workforce Provision: The BSR/ARC Workforce Register 2005-2007: Assessing the impact of recent changes in NHS provision. *Rheumatology (Oxford)*. 2008; 47(7):1065-9.
28. Bansback N, **Harrison MJ**, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A. Health state utility values: A description of their development and application for rheumatic diseases. *Arthritis and Rheumatology*. 2008; 59(7):1018-26.
29. **Harrison MJ**, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons D. The validity and responsiveness of generic utility measures in rheumatoid arthritis: A review. *Journal of Rheumatology*. 2008; 35(4):592-602.
30. Brennan A, Bansback N, Nixon R, Madan J, **Harrison M**, Watson K, Symmons D. Modelling the cost effectiveness of TNF- $\alpha$  Antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. *Rheumatology (Oxford)*. 2007; 46(8):1345-1354.
31. **Harrison MJ**, Hassell A, Dawes P, Scott D, Knight S, Davis M, Mulherin D, Symmons D. The overall status in rheumatoid arthritis (OSRA) measure – further evidence to support its use in clinical practice. *Rheumatology (Oxford)*. 2007; 46(5):849-55.
32. **Harrison MJ**, Morley KD, Symmons D. Developments in rheumatology consultant manpower provision: the VSR/ARC Workforce Register 2003-5. *Rheumatology (Oxford)*. 2006; 45(11):1416-21.
33. Symmons D, Tricker K, **Harrison MJ**, Roberts C, Davis M, Dawes P, Hassell A, Knight S, Mulherin D, Scott D. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatoid drugs – results of the British Rheumatoid Outcome Study Group Randomized Controlled Trial. *Rheumatology (Oxford)*. 2006; 45(5):558-65.
34. **Harrison MJ**, O'Hare A, Campbell H, Adamson A, McNeillage J. Prevalence of autistic spectrum disorders in Lothian, Scotland: An estimate using the “capture-recapture” technique. *Archives of Disease in Childhood*. 2006; 91(1):16-9.

35. **Harrison MJ**, Tricker KJ, Davies L, Hassell A, Dawes P, Scott DL, Knight S, Davis M, Mulherin D, Symmons DPM. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. *The Journal of Rheumatology*. 2005; 32(12):2330-2336.

(b) *Conference Proceedings*

1. **Harrison M**, Marra CA, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a discrete choice experiment. Canadian Rheumatology Association 2015. Quebec City, Canada, February 4-7, 2015. (poster)
2. **Harrison M**, Marra CA, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a discrete choice experiment. American College of Rheumatology 2014. Boston, USA, November 15-19, 2014.
3. Meacock R, **Harrison M**, McElhone K, Abbott J, Haque S, Bruce I, Teh L-S. Mapping the disease-specific LupusQoL to the SF-6D. American College of Rheumatology 2014. Boston, USA, November 15-19, 2014.
4. Bansback N, **Harrison M**, Marra CA. Does introducing imprecision around probabilities for benefit and harm influence the way people value treatments? Society for Medical Decision Making 2014. Miami, FL, USA, October 18-22, 2014.
5. Meacock R, **Harrison MJ**, McElhone K, Isenberg D, Ferenkeh-Koroma A, Ahmad Y, Bruce IN, Shelmerdine J, Gordon C, Peers K, Griffiths B, Maddison P, Akil M, Abbott J, The L-S. Exploratory mapping of the lupus QoL to the SF-6D. International Society for Pharmacoeconomics and Outcomes Research European Meeting 2012. Berlin, Germany, November 3, 2012.
6. Bujkiewicz S, Sutton AJ, Cooper NJ, Thompson JR, Spiegelhalter DR, **Harrison MJ**, Symmons DPMS, Abrams KR. Multivariate meta-analysis of surrogate endpoints in health technology assessment: A Bayesian approach. International Society for Clinical Biostatistics 2012. Bergen, Norway, August 10, 2012.
7. Meacock R, **Harrison MJ**, Hay C. Modelling the right dose for high-cost drugs: Application to immune tolerance induction in infants with severe haemophilia A. Nordic Health Economists' Study Group Meeting 2012. Kuopio, Finland, August 15, 2012.
8. **Harrison MJ**, Jacob I, Sutton M, Radford J, Renehan A. Modelling capacity for more resource-intensive services – An application of discrete event simulation to flexible sigmoidoscopy for colorectal cancer. European Conference of Health Economics 2012. Zurich, Switzerland, July 18, 2012.
9. Nikolova S, **Harrison MJ**, Sutton M. Does waiting time influence the effectiveness of surgery? Evidence from the national PROMs dataset. Health Economists' Study Group 2012. Oxford, UK, June 25, 2012.
10. **Harrison MJ**, Dusheiko M, Doran T, Gravelle H, Sutton M, Roland M. The impact of financial incentives for improvements in the quality of primary care on emergency hospital admission rates. International Health Economics Association Conference 2011. Toronto, Canada, July 10, 2011.
11. **Harrison MJ**, Dusheiko M, Doran T, Gravelle H, Sutton M, Roland M. Does better management of chronic conditions in general practice reduce emergency hospital admissions? Health Economists' Study Group Meeting 2011. Bangor, North Wales, UK, June 29, 2011.
12. **Harrison MJ**, Reeves D, Fullwood C, Bower PJ, Kennedy AP, Rogers AE. What factors influence patient engagement with the Expert Patients Programme course: Secondary analysis of data from a randomized controlled trial. International Conference on Support for Self Management of Health 2010. Stirling, Scotland, UK, May 11, 2010.
13. Reeves D, **Harrison MJ**, Fullwood C, Bower PJ, Kennedy AP, Rogers AE. Predicting who will benefit from an expert patients programme self-management course. International Conference on Support for Self Management of Health 2010. Stirling, Scotland, UK, May 11, 2010.
14. Pain CE, **Harrison MJ**, Symmons DPM, Foster HE, Baildam EM. Workforce planning in paediatric rheumatology in the United Kingdom (UK). British Society of Rheumatology Meeting 2010. Birmingham, UK, April 21, 2010.
15. Pain CE, **Harrison MJ**, Symmons DPM, Foster HE, Baildam EM. Workforce planning in paediatric rheumatology in the United Kingdom (UK). American College of Rheumatology Conference 2009. Philadelphia, PA, USA, October 17, 2009.

16. Barta Z, **Harrison MJ**, Wangrangsimakul T, Shelmerdine J, Teh L-S, Pattrick M, Edlin H, Dale N, Ahmad Y, Bruce IN (2009). Health-related quality of life, smoking and subclinical atherosclerosis in women with Systemic Lupus Erythematos. National Congress of Physical Medicine and Rehabilitation, Budapest, Hungary, 2009
17. **Harrison MJ**, Boonen A, Tugwell P, Symmons DPM. Same question, different answer: a comparison of global health assessments using VAS scales. EULAR, Copenhagen 2009 (Poster). *Ann Rheum Dis* 2009 .
18. **Harrison MJ**, Boonen A, Tugwell P, Symmons DPM. Same question, different answer: a comparison of global health assessments using VAS scales. British Society for Rheumatology, Glasgow 2009 (Poster). *Rheumatology (Oxford)* 2009;48(Suppl. 1):i110.
19. **Harrison MJ**, Watson K, Bansback N, Verstappen S, Symmons DPM. The validity of estimating EQ-5D scores from the HAQ and SF-36. British Society for Rheumatology, Glasgow 2009 (Poster). *Rheumatology (Oxford)* 2009;48(Suppl. 1):i111-112.
20. **Harrison MJ**, Farragher TM, Clarke AM, Bunn D, Manning S, Symmons DPM. Functional outcome is associated with personal and area level socioeconomic inequalities in inflammatory polyarthritis patients. American College of Rheumatology, San Francisco 2008 (Oral presentation). *Arthritis Rheum* 2008;58(9, (supplement)):S915-S916
21. **Harrison MJ**, Lunt M, Bansback N, Verstappen S, Watson K, Symmons DPM. The validity of estimating EQ-5D and SF-6D utility values from the HAQ. American College of Rheumatology, San Francisco 2008 (Poster). *Arthritis Rheum* 2008;58(9, (supplement)):S204
22. **Harrison MJ**, Deighton C, Symmons DPM. Patterns of provision and perceived job threat in the UK rheumatology consultant workforce: results from the BSR/arc Workforce Register. British Society for Rheumatology, Liverpool 2008 (Poster). *Rheumatology (Oxford)* 2008;47(Suppl. 2):II120.
23. **Harrison MJ**, Davies L, Bansback NJ, Symmons DPM. The comparative ability of the EQ-5D and SF-6D health utility measures to assess change in patients with rheumatoid arthritis. Health Economists' Study Group, Norwich 2008 (Oral presentation).
24. Health status in inflammatory arthritis patients with "worse than death" EQ-5D scores. **Harrison MJ**, Davies L, Bansback NJ, McCoy MJ, Hassell A, Symmons DPM. American College of Rheumatology, Boston USA 2007 (Poster). *Arthritis Rheum* 2007;56(9, (supplement)):S594-S595.
25. Bansback NJ, **Harrison MJ**, Brazier J, Davies L, Kopec J, Marra CA, Symmons DPM, Anis A. Health state utility values in rheumatic diseases – a review. EULAR Barcelona 2007 (Poster). *Ann Rheum Dis* 2007;66(Suppl. 2):256.
26. **Harrison MJ**, Davies L, Bansback NJ, McCoy MJ, Hassell A, Symmons DPM. Why do patients with rheumatoid arthritis often score "states worse than death" on the EQ-5D? British Society for Rheumatology, Birmingham 2007 (Oral presentation). *Rheumatology (Oxford)* 2007;46(Supplement 1):i8.
27. **Harrison MJ**, Davies L, Bansback NJ, Symmons DPM. The comparative measurement properties of the EQ-5D and SF-6D health utility measures in patients with rheumatoid arthritis. *Arthritis and Rheumatism* 2006. American College of Rheumatology Washington DC 2006 (Poster). *Arthritis Rheum* 2006;54(9, (supplement)):S106.
28. **Harrison M**, Morley K.D., & Symmons D. BSR/arc consultant workforce register - 2003-2005. British Society for Rheumatology Glasgow 2006 (Poster). *Rheumatology (Oxford)* 45, 1131-1132. 2006.
29. **Harrison M**, Tricker, K., Davies, L., Dawes, P., Scott, D., Mulherin, D. *et al.* (2005). Social deprivation: an important predictor of response to treatment in a clinical trial situation. British Society for Rheumatology Birmingham 2005 (Poster). *Rheumatology (Oxford)* 2005 Mar;44:150-151.
30. **Harrison MJ.**, Tricker, K. J., Davies, L., Roberts, C., & Symmons, D. P. M. The impact of social deprivation on health related quality of life and functional disability in patients with established rheumatoid arthritis. British Society for Rheumatology Edinburgh 2004 (Poster). *Rheumatology (Oxford)* 2004 Apr 1;43(suppl\_2):ii84.
31. **Harrison MJ**, O'Hare AE, Campbell H, Adamson A, McNeillage J. Autistic Spectrum Disorders in Lothian, Scotland, First Study of Prevalence with use of the capture recapture technique. Sheffield 2004 (Oral presentation). *Developmental Mental Medicine Child Neurology* 2004; 98(46):19.

(c) Other

## 2. NON-REFEREED PUBLICATIONS

(a) *Journals*

(b) *Conference Proceedings*

(c) *Other*

1. **Harrison MJ.** Does better management of chronic conditions in general practice reduce emergency hospital admissions? Report for the Department of Health. 2011.
2. Hyrich K, Lunt M, Davies R, **Harrison MJ**, Watson K, Symmons D, on behalf of the BSR Biologics Register. The British Society for Rheumatology Biologics Register: Updated Analysis on Sequential Use of Anti-TNF Therapies in Patients with Rheumatoid Arthritis. Report for the National Institute for Health and Clinical Excellence (NICE). 2009.

### 3. **BOOKS**

(a) *Authored*

(b) *Edited*

(c) *Chapters*

1. **Harrison MJ.** Inflammatory Arthritis EQ-5D and SF-6D. Encyclopedia of Quality of Life Research. AC Michalos (Editor). 2012.

### 4. **PATENTS**

### 5. **SPECIAL COPYRIGHTS**

### 6. **ARTISTIC WORKS, PERFORMANCES, DESIGNS**

### 7. **OTHER WORKS**

### 8. **WORK SUBMITTED (including publisher and date of submission)**

1. Nikolova S, **Harrison MJ**, Sutton M. Does waiting time influence the effectiveness of surgery? Evidence from the national PROMs dataset. Health Economics

9. **WORK IN PROGRESS** (including degree of completion)